$439 Million is the total value of Boxer Capital, LLC's 30 reported holdings in Q3 2017. The portfolio turnover from Q2 2017 to Q3 2017 was 40.7% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| AVXS | AVEXIS INC | $77,384,000 | +17.7% | 800,000 | 0.0% | 17.62% | +12.7% | |
| BGNE | BEIGENE LTDsponsored adr | $62,076,000 | +129.9% | 600,000 | 0.0% | 14.13% | +120.1% | |
| CLVS | CLOVIS ONCOLOGY INC | $41,200,000 | -12.0% | 500,000 | 0.0% | 9.38% | -15.8% | |
| MGNX | Buy | MACROGENICS INC | $40,656,000 | +9.8% | 2,200,000 | +4.0% | 9.26% | +5.1% |
| MDCO | Sell | MEDICINES COMPANY | $33,336,000 | -27.8% | 900,000 | -25.9% | 7.59% | -30.9% |
| ESPR | Sell | ESPERION THERAPEUTICS INC NE | $25,060,000 | -45.9% | 500,000 | -50.0% | 5.70% | -48.2% |
| PTCT | Sell | PTC THERAPEUTICS INC | $25,013,000 | -19.7% | 1,250,000 | -26.5% | 5.69% | -23.2% |
| BPMC | BLUEPRINT MEDICINES CORP | $17,418,000 | +37.5% | 250,000 | 0.0% | 3.96% | +31.6% | |
| GTHX | G1 THERAPEUTICS INC | $15,660,000 | +42.7% | 629,179 | 0.0% | 3.56% | +36.6% | |
| KURA | Buy | KURA ONCOLOGY INC | $12,630,000 | +154.7% | 844,789 | +58.4% | 2.88% | +143.9% |
| MRTX | MIRATI THERAPEUTICS INC | $12,145,000 | +220.5% | 1,037,994 | 0.0% | 2.76% | +206.9% | |
| PBYI | PUMA BIOTECHNOLOGY INC | $11,975,000 | +37.0% | 100,000 | 0.0% | 2.73% | +31.2% | |
| LJPC | LA JOLLA PHARMACEUTICAL CO | $9,304,000 | +16.8% | 267,500 | 0.0% | 2.12% | +11.8% | |
| CBAY | Buy | CYMABAY THERAPEUTICS INC | $8,165,000 | +233.5% | 1,012,986 | +138.3% | 1.86% | +219.4% |
| ZGNX | New | ZOGENIX INC | $7,010,000 | – | 200,000 | +100.0% | 1.60% | – |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $6,220,000 | – | 200,000 | +100.0% | 1.42% | – |
| SBBP | Sell | STRONGBRIDGE BIOPHARMA PLC | $5,913,000 | -12.0% | 856,900 | -8.8% | 1.35% | -15.8% |
| GTXI | New | GTX INC DEL | $4,771,000 | – | 565,291 | +100.0% | 1.09% | – |
| AQXP | Sell | AQUINOX PHARMACEUTICALS INC | $4,434,000 | -40.0% | 312,500 | -40.5% | 1.01% | -42.6% |
| AXGT | New | AXOVANT SCIENCES LTD | $3,440,000 | – | 500,000 | +100.0% | 0.78% | – |
| RGLS | New | REGULUS THERAPEUTICS INC | $2,747,000 | – | 2,197,802 | +100.0% | 0.62% | – |
| BLPH | BELLEROPON THERAPEUTICS INC | $2,637,000 | +5.9% | 1,857,143 | 0.0% | 0.60% | +1.4% | |
| ARDMQ | New | ARADIGM CORP | $2,100,000 | – | 500,000 | +100.0% | 0.48% | – |
| SNSS | SUNESIS PHARMACEUTICALS INC | $1,989,000 | -28.1% | 1,025,000 | 0.0% | 0.45% | -31.2% | |
| VXX | New | BARCLAYS BK PLCipath s&p 500 vix | $1,960,000 | – | 50,000 | +100.0% | 0.45% | – |
| EIGR | EIGER BIOPHARMACEUTICALS INC | $1,522,000 | +39.2% | 138,331 | 0.0% | 0.35% | +33.1% | |
| SNDX | Sell | SYNDAX PHARMACEUTICALS INC | $1,170,000 | -64.2% | 100,000 | -57.3% | 0.27% | -65.8% |
| NBRV | Sell | NABRIVA THERAPEUTICS AGsponsored adr | $710,000 | -61.7% | 86,710 | -50.9% | 0.16% | -63.2% |
| ONTXW | Buy | ONCONOVA THERAPEUTICS INC*w exp 07/07/202 | $528,000 | +384.4% | 308,793 | +27.8% | 0.12% | +361.5% |
| ONTX | Sell | ONCONOVA THERAPEUTICS INC | $92,000 | -85.9% | 241,644 | -20.2% | 0.02% | -86.5% |
| VXX | Exit | BARCLAYS BK PLCipath s&p 500 vix | $0 | – | -250,000 | -100.0% | -0.76% | – |
| SGEN | Exit | SEATTLE GENETICS INC | $0 | – | -125,000 | -100.0% | -1.54% | – |
| INCY | Exit | INCYTE CORP | $0 | – | -100,000 | -100.0% | -2.99% | – |
| Exit | MEDICINES COMPANYcall | $0 | – | -530,600 | -100.0% | -4.80% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
- Aviva Holdings Ltd. #1
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-11-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| MIRATI THERAPEUTICS INC | 32 | Q3 2023 | 55.2% |
| BEIGENE LTD | 31 | Q3 2023 | 15.6% |
| KURA ONCOLOGY INC. | 24 | Q3 2021 | 4.7% |
| ROCKET PHARMACEUTICALS INC | 23 | Q3 2023 | 5.4% |
| DBV TECHNOLOGIES S A | 23 | Q3 2023 | 3.9% |
| MEI PHARMA INC | 21 | Q2 2023 | 1.4% |
| SYNDAX PHARMACEUTICALS INC | 20 | Q3 2021 | 3.1% |
| GOSSAMER BIO INC | 19 | Q3 2023 | 4.7% |
| ODONATE THERAPEUTICS INC | 18 | Q1 2022 | 12.5% |
| ESPERION THERAPEUTICS INC NE | 18 | Q2 2021 | 11.0% |
View Boxer Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| IDEAYA Biosciences, Inc. | February 14, 2023 | 2,202,812 | 4.6% |
| Milestone Pharmaceuticals Inc. | February 14, 2023 | 698,861 | 2.0% |
| SpringWorks Therapeutics, Inc. | September 19, 2022 | 3,421,541 | 5.7% |
| iTeos Therapeutics, Inc. | May 11, 2022 | 2,154,058 | 6.1% |
| Atreca, Inc. | February 14, 2022 | 2,202,333 | 7.2% |
| Biomea Fusion, Inc. | February 14, 2022 | 1,188,405 | 4.1% |
| Cabaletta Bio, Inc. | February 14, 2022 | 540,000 | 1.9% |
| CymaBay Therapeutics, Inc. | February 14, 2022 | ? | ? |
| DBV Technologies S.A. | February 14, 2022 | 1,067,299 | 1.9% |
| Elevation Oncology, Inc. | February 14, 2022 | 872,780 | 3.8% |
View Boxer Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-22 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G | 2024-02-12 |
| 4 | 2024-02-08 |
| SC 13D/A | 2024-02-08 |
| 4 | 2024-01-25 |
| SC 13D/A | 2024-01-25 |
| SC 13G | 2024-01-18 |
| SC 13D/A | 2023-12-18 |
View Boxer Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.